This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Hikma Pharmaceuticals files US antitrust claims against Amarin over Vascepa

( February 21, 2023, 22:31 GMT | Official Statement) -- MLex Summary: Amarin Pharma has been accused of illegally delaying generic competition for the branded cardiovascular drug Vascepa. Hikma Pharmaceuticals claims Amarin used exclusivity agreements to prevent any suppliers of a necessary active ingredient with sufficient capacity from supporting a commercial launch in a timely manner. According to the US district court complaint, without Amarin’s interference, a competitor would have been able to manufacture a generic after winning two patent cases against Amarin.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections